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Résumé en
anglais
BACKGROUND: Noninvasive methods for liver fibrosis evaluation in chronic liver
diseases have been recently developed, i.e. transient elastography (Fibroscan™)
and blood tests (Fibrometer®, Fibrotest®, and Hepascore®). In this study, we
aimed to design a new score in chronic hepatitis C (CHC) by selecting blood
markers in a large panel and we compared its diagnostic performance with those
of other noninvasive methods.
METHODS: Sixteen blood tests were performed in 306 untreated CHC patients
included in a multicenter prospective study (ANRS HC EP 23 Fibrostar) using
METAVIR histological fibrosis stage as reference. The new score was constructed
by non linear regression using the most accurate biomarkers.
RESULTS: Five markers (alpha-2-macroglobulin, apolipoprotein-A1, AST, collagen
IV and osteoprotegerin) were included in the new function called Coopscore©.
Using the Obuchowski Index, Coopscore© shows higher diagnostic performances
than for Fibrometer®, Fibrotest®, Hepascore® and Fibroscan™ in CHC.
Association between Fibroscan™ and Coopscore© might avoid 68% of liver
biopsies for the diagnosis of significant fibrosis.
CONCLUSION: Coopscore© provides higher accuracy than other noninvasive
methods for the diagnosis of liver fibrosis in CHC. The association of Coopscore©
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